AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) shares were down 2.4% during trading on Thursday . The stock traded as low as $3.24 and last traded at $3.25, with a volume of 93,903 shares traded. The stock had previously closed at $3.33.

Several research analysts have commented on ACRX shares. RBC Capital Markets reaffirmed a “positive” rating and set a $6.00 price target on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 16th. Jefferies Group reaffirmed a “buy” rating on shares of AcelRx Pharmaceuticals in a research report on Wednesday, August 10th. Cowen and Company reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, July 29th. Stifel Nicolaus lowered AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 5th. Finally, HC Wainwright reissued a “buy” rating on shares of AcelRx Pharmaceuticals in a report on Monday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. AcelRx Pharmaceuticals presently has an average rating of “Hold” and an average target price of $7.30.

The firm has a 50-day moving average price of $3.30 and a 200 day moving average price of $3.34. The firm’s market cap is $146.81 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. The company earned $4.53 million during the quarter, compared to analyst estimates of $2.17 million. On average, equities research analysts expect that AcelRx Pharmaceuticals Inc. will post ($0.91) EPS for the current fiscal year.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.